In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases.
about
Influence of physical properties of carrier on the performance of dry powder inhalersIn Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory ApproachesEffect of device design on the in vitro performance and comparability for capsule-based dry powder inhalers.International Guidelines for Bioequivalence of Locally Acting Orally Inhaled Drug Products: Similarities and DifferencesEdge activators and a polycationic polymer enhance the formulation of porous voriconazole nanoagglomerate for the use as a dry powder inhaler.Regulatory Considerations for Approval of Generic Inhalation Drug Products in the US, EU, Brazil, China, and India.In vitro and in vivo testing methods for respiratory drug delivery.Establishing bioequivalence for inhaled drugs; weighing the evidence.Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs).Bioequivalence of inhaled drugs: fundamentals, challenges and perspectives.Innovative approaches for demonstration of bioequivalence: the US FDA perspective.Performance properties of the population bioequivalence approach for in vitro delivered dose for orally inhaled respiratory products.Validating Whole-Airway CFD Predictions of DPI Aerosol Deposition at Multiple Flow Rates.Application of the modified chi-square ratio statistic in a stepwise procedure for cascade impactor equivalence testing.Defining the critical material attributes of lactose monohydrate in carrier based dry powder inhaler formulations using artificial neural networksEffect of Device Design and Formulation on the In Vitro Comparability for Multi-Unit Dose Dry Powder Inhalers.A sensitivity analysis of the modified chi-square ratio statistic for equivalence testing of aerodynamic particle size distribution.A Systematic Analysis of the Sensitivity of Plasma Pharmacokinetics to Detect Differences in the Pulmonary Performance of Inhaled Fluticasone Propionate Products Using a Model-Based Simulation Approach.Effects of device and formulation on in vitro performance of dry powder inhalers.Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro studyA stability analysis of a modified version of the chi-square ratio statistic: implications for equivalence testing of aerodynamic particle size distribution.A pharmacokinetic simulation tool for inhaled corticosteroids.A review on recent technologies for the manufacture of pulmonary drugs.Brand and generic use of inhalation medication and frequency of switching in children and adults: A population-based cohort study.Considerations in establishing bioequivalence of inhaled compounds.Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.Response to Sharma et al.: Long Pulmonary Residence Time and Plasma Half-Life of Tiotropium: Implications for Pharmacokinetic Bioequivalence Studies.Essential criteria for pharmacokinetic studies supporting bioequivalence of inhaled tiotropium bromide products
P2860
Q26740570-2651369F-8098-449A-9026-8E44DAC5AFC9Q28080832-8AF03DE2-DF74-4196-AB5B-04F90A1BE754Q30525704-B44DA68C-91CD-4534-A63C-1ED6E8AB7CC7Q35529144-313D88C7-B5E6-4C94-817F-8E45D5D5CBDFQ35922737-51317593-0346-4844-B234-FE06C6305243Q35967928-E152A27C-E1A9-4547-A016-31F24006AD06Q37822755-1A8C131D-9D70-4A8D-B79F-214F5163771BQ37893662-6FE98204-0127-4373-8A51-9AA79F8B74BCQ38026512-F620A476-35F7-4B7B-93D8-56D3E2FA301EQ38084738-80A787E8-AA47-49EB-8532-1F169EEBE667Q38112172-6DA52FC4-81CA-45DE-9F82-3462E34BC64DQ38163924-0459394F-9C75-49C5-B386-953566916E99Q39848034-E811C037-ABAC-4B8A-98E2-C54A70F4ECF6Q41854778-0E939A6A-044E-41CA-A57A-FFC65E44CFD6Q41864515-07D35E4D-BC4F-455E-8625-6AD9A56D9180Q41984406-5A355081-3AF3-4F8E-AF16-802CBD057FCBQ41997758-6477BDDD-D3B4-4BC6-92A0-90A2F9DE859CQ42035782-34D9AD94-1E9C-4518-90F5-1B7BFD7B5B44Q42218975-F9DD2A66-779E-430A-A694-AE208FAD0CF5Q42365121-6B98E8E6-86A2-4C30-8A9E-F5D65C2F83ABQ42506344-03A7E90D-5F49-4D03-A121-E3AAB31DE3D1Q42507245-10EDA0E6-415C-467E-A1F8-75B826EBD337Q47272028-5100865E-F4A1-46DE-8821-687FEB4FE85DQ47303265-33108E8B-7565-40F9-860C-364055D498EDQ47666210-A9753C82-CD71-4B60-8F02-D25F132A8B88Q48020453-187CC07C-C9B4-4E01-9660-A8AF899350E3Q48333318-C3B5654D-ACE5-4CCF-AA56-CCA25BE577D8Q58869538-24C2A4AA-B426-4BD1-A3A0-95497E19EC58
P2860
In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In vitro considerations to sup ...... er inhalers for lung diseases.
@en
In vitro considerations to sup ...... er inhalers for lung diseases.
@nl
type
label
In vitro considerations to sup ...... er inhalers for lung diseases.
@en
In vitro considerations to sup ...... er inhalers for lung diseases.
@nl
prefLabel
In vitro considerations to sup ...... er inhalers for lung diseases.
@en
In vitro considerations to sup ...... er inhalers for lung diseases.
@nl
P2093
P2860
P1433
P1476
In vitro considerations to sup ...... er inhalers for lung diseases.
@en
P2093
Badrul A Chowdhury
Dale P Conner
Lawrence X Yu
Sau Lawrence Lee
Wallace P Adams
P2860
P2888
P304
P356
10.1208/S12248-009-9121-4
P407
P577
2009-06-03T00:00:00Z
P5875
P6179
1006721716